Published in Anemia on December 30, 2015
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health (2013) 4.22
Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2004) 3.37
The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA (1990) 3.03
The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin (2004) 2.16
Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2004) 1.83
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol (2006) 1.52
C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol (2008) 1.34
Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther (1991) 1.22
An economic evaluation of erythropoiesis-stimulating agents in CKD. Am J Kidney Dis (2010) 1.20
The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int (2003) 1.05
Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int (2004) 0.99
Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. Int J Clin Pract (2010) 0.90
Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A. Blood Purif (2008) 0.89
Treatment of anemia in chronic kidney disease--strategies based on evidence. N Engl J Med (2009) 0.87
Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens (2002) 0.86
Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res (2014) 0.81
Quality of life and hematocrit level. Am J Kidney Dis (1992) 0.80
Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries. J Med Econ (2013) 0.80
Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis. Int J Clin Pharm (2013) 0.80
Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia. Clin Kidney J (2014) 0.80
Conversion from epoetin alfa to darbepoetin alfa: effects on patients' hemoglobin and costs to canadian dialysis centres. Can J Hosp Pharm (2012) 0.77